About

Welcome to the Lupus Forum. The Lupus Forum is an educational website developed under the auspices of the University of Leeds and is dedicated to the dissemination of the latest developments in the field of lupus. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of lupus, its treatments, and clinical practice.

Lupus Forum content is free from commercial bias, and feature leading experts sharing their knowledge and experience in the form of video tutorials.

Membership of the Lupus Forum is free to everyone. Register as a member and have unlimited free access to all of the materials contained within the site.

CLE Webinar
View our ACR 2024 resources
2024 Lupus Forum Members Survey Results
Lupus Europe, now available on the useful links page

NEW Monthly literature search podcasts – available now

Steering Committee member Professor Maria Dall’Era, Professor of Medicine and Chief of the Division of Rheumatology at the of University of California, San Francisco, USA, is joined by fellow member Professor Brad Rovin, who is Lee A. Hebert Professor of Nephrology and Medical Director at Ohio State University Clinical Research Management Institute, Columbus, Ohio, on the latest Lupus Forum podcast. Together, they discuss the efficacy and safety of a voclosporin-based triple immunosuppressive regimen and summarise the latest ACR guidance to screen, treat, and manage lupus nephritis.

Latest Updates

Publications ▼
All
Publication thumbnail: Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial

Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial

Publication thumbnail: Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: A propensity analysis of the AURA-LV and AURORA 1 studies and ALMS

Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: A propensity analysis of the AURA-LV and AURORA 1 studies and ALMS

Publication thumbnail: Efficacy and safety of sodium-glucose co-transporter 2 inhibitors for the primary prevention of cardiovascular, renal events and safety outcomes in patients with systemic lupus erythematosus and comorbid type 2 diabetes: A population-based target trial emulation

Efficacy and safety of sodium-glucose co-transporter 2 inhibitors for the primary prevention of cardiovascular, renal events and safety outcomes in patients with systemic lupus erythematosus and comorbid type 2 diabetes: A population-based target trial emulation

Publication thumbnail: Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: a randomized phase 2 clinical trial

Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: a randomized phase 2 clinical trial

Steering Committee